Latest Content

New research highlights psilocybin's potential in treating treatment-resistant OCD, while cannabinoids show little evidence of efficacy.

Explore the new Psychiatric Times digital issue, featuring articles, multimedia, and interactive learning to sharpen your clinical skills.

Learn how bupropion can trigger dose-related tinnitus and when lowering or stopping the antidepressant brings relief, with real-world clinical guidance.

New evidence reframes antidepressant withdrawal: how common, how severe, and how to taper safely without mistaking symptoms for relapse.

FDA grants priority review to Takeda’s orexin agonist oveporexton, promising phase 3 gains in wakefulness and cataplexy for narcolepsy type 1.

A rare psychiatrist-publisher dies at 97; explore Jason Aronson’s publishing legacy, Jewish studies ties, and free classic psychotherapy downloads.

Explore how AI transforms healthcare by enhancing diagnostics, personalizing treatments, and improving access while addressing significant risks and limitations.

Antidepressant withdrawal often mimics relapse; learn why hyperbolic tapering, informed consent, and slow cut-and-hold deprescribing reduce harm.

Inside the opioid epidemic: psychiatry and addiction care, MOUD options, and why stigma, policy, and jails still block lifesaving treatment.

This tribute to Rose Childs explores pioneering community mental health teamwork, cultural psychiatry innovation, shared leadership, and her lasting legacy in patient-centered care.

Heinrichs' POP model reaffirms the role of clinical judgment and patient-centered care.

Remembering Elise Snyder, MD, 91, who pioneered CAPA and video-based psychoanalytic training that bridged US-China mental health stigma and culture.

Review the latest in sports psychiatry before the 2026 winter Olympics.